Trial reportEating and weight disorders : EWD2015
Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial.
Trial report in Eating and weight disorders : EWD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02502617 (Effect of Intensive Re-nutrition on Eating Disorder Psychopathology, Cognitive Functions, Anxiety, Depression, and Cortisol Level in Severe Anorexia Nervosa), which is not on this map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Intensive Re-nutrition on Eating Disorder Psychopathology, Cognitive Functions, Anxiety, Depression, and Cortisol Level in Severe Anorexia Nervosa
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Contextualising Physical Activity Levels in Patients With Anorexia Nervosa: A Systematic Review and Meta-Analysis.European eating disorders review : the journal of the Eating Disorders Association · 2025Pooled it
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Treatment studies with cannabinoids in anorexia nervosa: a systematic review.Eating and weight disorders : EWD · 2021Pooled it
- How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.European archives of psychiatry and clinical neuroscience · 2019Pooled it
- Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.BMC psychiatry · 2024Article
- Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.Focus (American Psychiatric Publishing) · 2024Review
- Exploring the influence of circulating endocannabinoids and nucleus accumbens functional connectivity on anorexia nervosa severity.Molecular psychiatry · 2023Article
- The relationship between cannabis and anorexia nervosa: a scoping review.Journal of eating disorders · 2023Article
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Article
- Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.Biomolecules · 2020Review
- MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update.European journal of endocrinology · 2019Review
- Pharmacotherapy of eating disorders.Current opinion in psychiatry · 2017Review
- Psychopharmacologic treatment of eating disorders: emerging findings.Current psychiatry reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe level of physical activity is inappropriately high in up to 80% of the patients suffering of anorexia nervosa (AN), as a result of conscious efforts to lose weight, affect regulation and biological adaptive changes to starvation induced by hypothermia and neuroendocrine mechanisms. The purposes of this paper were to (1) assess the effect of dronabinol-a synthetic cannabinoid agonist-on physical activity in patients with chronic and stable AN, and to (2) unravel the role of leptin and cortisol in this process.
methodsThis prospective, randomised, double-blind, crossover study was conducted at a specialised care centre for eating disorders. Twenty-four adult women with AN of at least 5-year duration received either the dronabinol-placebo or placebo-dronabinol sequence. Physical activity was monitored during the fourth week of each intervention. Body weight, leptin and urinary free cortisol excretion were measured repeatedly during the trial. Changes in behavioural dimensions related to AN were assessed by Eating Disorder Inventory-2.
resultsThe total duration of physical activity did not change, while its average intensity increased by 20% (P = 0.01) during dronabinol therapy, resulting in an increased energy expenditure with 68.2 kcal/day (P = 0.01) above placebo.
conclusionsThis randomised, double-blind study revealed that cannabinoid agonist treatment was associated with a modest increase in physical activity in adult women with severe and longstanding AN. Additionally, we detected a strong relationship between the circulating levels of leptin and physical activity in these chronically undernourished patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.